News
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.
WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" ...
Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as ...
Last and least, I look at the drug stocks and I can’t believe how awful they really are, with now Eli Lilly last joining the ...
The drugmaker is one step closer to breaking ground on over 200 acres of land in a Houston development that's seeking ...
Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...
The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...
Hosted on MSN3h
1 Reason to Buy Eli Lilly (LLY) Stock
Eli Lilly specializes in obesity and diabetes treatments, among other areas. It's reasonable to expect a lot more growth from the company. Its shares aren't exactly cheap at recent levels, though.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback